Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue Endocrinology, Diabetes & Metabolism Année : 2021

Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design

Résumé

The natural history of non-alcoholic fatty liver disease (NAFLD) is still not fully elucidated. Patients with NAFLD have a low risk of liver complications, unless substantial liver fibrosis has developed. On the other hand, NAFLD has been linked with excess metabolic and cardiovascular complications. Therapies targeting common pathways may benefit both NAFLD and underlying cardiometabolic risk. Therefore, there is a rationale for considering cardiovascular endpoints in the context of NAFLD trials and, vice-versa, to consider the concomitant presence of NAFLD in drug development for cardiometabolic disorders. This manuscript provides a framework for consideration for future trials examining the inter-relationship between cardiovascular disease and NAFLD.
Fichier principal
Vignette du fichier
Manuscript_HAL.pdf (888.94 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03469195 , version 1 (07-12-2021)

Identifiants

Citer

Pierpaolo Pellicori, Muthiah Vaduganathan, João Pedro Ferreira, Faiez Zannad, Arun J Sanyal. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. Endocrinology, Diabetes & Metabolism, 2021, pp.101281. ⟨10.1016/j.diabet.2021.101281⟩. ⟨hal-03469195⟩
138 Consultations
152 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More